

Mark B Pepys

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8432822/mark-b-pepys-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

133
papers

25,964
citations

63
h-index

137
g-index

137
ext. papers

28,317
ext. citations

13.1
avg, IF

6.7
L-index

#	Paper	IF	Citations
133	Dementia in the older population is associated with neocortex content of serum amyloid P component. <i>Brain Communications</i> , 2021 , 3, fcab225	4.5	2
132	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. <i>Nature Communications</i> , 2021 , 12, 7112	17.4	2
131	Comparative study of the stabilities of synthetic and natural transthyretin amyloid fibrils. <i>Journal of Biological Chemistry</i> , 2020 , 295, 11379-11387	5.4	8
130	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 8274-8283	8.3	17
129	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	68
128	Plasminogen activation triggers transthyretin amyloidogenesis. <i>Journal of Biological Chemistry</i> , 2018 , 293, 14192-14199	5.4	42
127	The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs. <i>Frontiers in Immunology</i> , 2018 , 9, 2382	8.4	26
126	Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. <i>PLoS ONE</i> , 2018 , 13, e0197299	3.7	10
125	Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 5-6	2.7	2
124	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. <i>Journal of Proteomics</i> , 2017 , 165, 113-118	3.9	12
123	Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular A β amyloid deposits in vivo. <i>Open Biology</i> , 2016 , 6, 150202	7	18
122	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. <i>New England Journal of Medicine</i> , 2015 , 373, 1106-14	59.2	250
121	Bifunctional crosslinking ligands for transthyretin. <i>Open Biology</i> , 2015 , 5, 150105	7	2
120	A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. <i>EMBO Molecular Medicine</i> , 2015 , 7, 1337-49	12	81
119	Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction. <i>Cell Reports</i> , 2015 , 13, 1937-48	10.6	90
118	Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP). <i>Blood</i> , 2015 , 126, 1836-1836	2.2	4
117	C-reactive protein is essential for innate resistance to pneumococcal infection. <i>Immunology</i> , 2014 , 142, 414-20	7.8	29

116	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 1539-44	11.5	72
115	Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. <i>Circulation Research</i> , 2014 , 114, 672-6	15.7	46
114	Attention to detail in the selection of words in epidemiologic research reports. <i>American Journal of Epidemiology</i> , 2014 , 179, 795-6	3.8	2
113	Protection of human podocytes from shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component. <i>Infection and Immunity</i> , 2014 , 82, 1872-9	3.7	15
112	Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC). <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2014 , 70, 2232-40		7
111	Targeted treatment for amyloidosis. <i>Israel Medical Association Journal</i> , 2014 , 16, 277-80	0.9	3
110	Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. <i>Journal of Immunological Methods</i> , 2013 , 390, 63-73	2.5	30
109	Pathogenetic mechanisms of amyloid A amyloidosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 16115-20	11.5	63
108	Structure, folding dynamics, and amyloidogenesis of D76N β -microglobulin: roles of shear flow, hydrophobic surfaces, and β -crystallin. <i>Journal of Biological Chemistry</i> , 2013 , 288, 30917-30	5.4	63
107	Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013 , 20, 93-8	2.7	7
106	Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. <i>Journal of Immunological Methods</i> , 2012 , 384, 92-102	2.5	28
105	C-reactive protein, fibrinogen, and cardiovascular disease prediction. <i>New England Journal of Medicine</i> , 2012 , 367, 1310-20	59.2	750
104	Hereditary systemic amyloidosis due to Asp76Asn variant β -microglobulin. <i>New England Journal of Medicine</i> , 2012 , 366, 2276-83	59.2	135
103	Immunoradiometric assay for human serum amyloid P component. <i>Journal of Immunological Methods</i> , 2011 , 371, 18-24	2.5	4
102	Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component. <i>Journal of Molecular Recognition</i> , 2011 , 24, 371-7	2.6	29
101	Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. <i>BMJ, The</i> , 2011 , 342, d548	5.9	422
100	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. <i>British Journal of Haematology</i> , 2010 , 148, 760-7	4.5	89
99	Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. <i>Nature</i> , 2010 , 468, 93-7	50.4	246

98	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 20483-8	11.5	50
97	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. <i>Lancet, The</i> , 2010 , 375, 132-40	40	1584
96	Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 245-9		16
95	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 7619-23	11.5	55
94	C-reactive protein and coronary disease: is there a causal link?. <i>Circulation</i> , 2009 , 120, 2036-9	16.7	43
93	A molecular correlate of clinicopathology in transthyretin amyloidosis. <i>Journal of Pathology</i> , 2009 , 217, 1-3	9.4	10
92	Jack Pepys (May 15, 1914-September 9, 1996): a personal recollection. <i>Journal of Allergy and Clinical Immunology</i> , 2009 , 123, 718-20	11.5	0
91	C-reactive protein is neither a marker nor a mediator of atherosclerosis. <i>Nature Clinical Practice Nephrology</i> , 2008 , 4, 234-5		21
90	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE ^{-/-} mice. <i>Atherosclerosis</i> , 2008 , 196, 248-255	3.1	87
89	Complement factor H binds to denatured rather than to native pentameric C-reactive protein. <i>Journal of Biological Chemistry</i> , 2008 , 283, 30451-60	5.4	78
88	Normal circulating serum amyloid P component concentration in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2013-7		10
87	Is leptin an important physiological regulator of CRP?. <i>Nature Medicine</i> , 2007 , 13, 17-8; author reply 19-21	10.5	14
86	C-reactive protein and cardiovascular disease: Weighing the evidence. <i>Current Cardiovascular Risk Reports</i> , 2007 , 1, 72-79	0.9	1
85	Science and serendipity. <i>Clinical Medicine</i> , 2007 , 7, 562-78	1.9	17
84	Human plasma fibrinogen is synthesized in the liver. <i>Blood</i> , 2007 , 109, 1971-4	2.2	206
83	Beta-edge interactions in a pentadecameric human antibody V kappa domain. <i>Journal of Molecular Biology</i> , 2007 , 367, 603-8	6.5	11
82	C-reactive protein and cardiovascular disease: weighing the evidence. <i>Current Atherosclerosis Reports</i> , 2006 , 8, 421-8	6	69
81	Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome. <i>Journal of Infectious Diseases</i> , 2006 , 193, 1120-4	7	46

80	Amyloidosis. <i>Annual Review of Medicine</i> , 2006 , 57, 223-41	17.4	493
79	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. <i>Blood</i> , 2006 , 107, 1227-9	2.2	101
78	Targeting C-reactive protein for the treatment of cardiovascular disease. <i>Nature</i> , 2006 , 440, 1217-21	50.4	525
77	CRP or not CRP? That is the question. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 1091-4	9.4	83
76	Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. <i>Circulation</i> , 2005 , 111, 1530-6	16.7	150
75	Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. <i>Circulation Research</i> , 2005 , 97, e97-103	15.7	105
74	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 8309-14	11.5	172
73	Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. <i>Clinical Chemistry</i> , 2004 , 50, 130-4	5.5	124
72	Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. <i>Immunology</i> , 2004 , 112, 255-64	7.8	60
71	Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice. <i>Immunology</i> , 2004 , 112, 250-4	7.8	1
70	Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004 , 24, 1214-8	7.3	118
69	Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. <i>Circulation</i> , 2004 , 109, 3022-8	16.7	146
68	C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. <i>New England Journal of Medicine</i> , 2004 , 350, 1387-97	59.2	2317
67	Determination of C-reactive protein: comparison of three high-sensitivity immunoassays. <i>Clinical Chemistry</i> , 2003 , 49, 1691-5	5.5	28
66	Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. <i>Journal of Immunology</i> , 2003 , 171, 6046-51	5.3	31
65	Dame Sheila Patricia Violet Sherlock. <i>Biographical Memoirs of Fellows of the Royal Society</i> , 2003 , 49, 475-93	31	2
64	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. <i>British Journal of Haematology</i> , 2003 , 122, 78-84	4.5	315
63	MHC typing in variant Creutzfeldt-Jakob disease. <i>Lancet, The</i> , 2003 , 361, 487-9	40	19

62	Markers of inflammation in women on different hormone replacement therapies. <i>Annals of Medicine</i> , 2003 , 35, 353-61	1.5	22
61	Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. <i>American Journal of Epidemiology</i> , 2003 , 158, 357-64	3.8	87
60	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , 2003 , 111, 1805-12	15.9	1134
59	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , 2003 , 111, 1805-1812	15.9	2388
58	Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. <i>New England Journal of Medicine</i> , 2002 , 346, 1786-91	59.2	516
57	Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection. <i>Journal of Immunology</i> , 2002 , 169, 913-9	5.3	44
56	C-reactive protein risk prediction: low specificity, high sensitivity. <i>Annals of Internal Medicine</i> , 2002 , 136, 550-2	8	17
55	Influenza virus infection is not affected by serum amyloid P component. <i>Molecular Medicine</i> , 2002 , 8, 9-15	6.2	8
54	Lack of seasonal variation in C-reactive protein. <i>Clinical Chemistry</i> , 2002 , 48, 575-7	5.5	6
53	Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. <i>Nature Medicine</i> , 2001 , 7, 485-7	50.5	183
52	C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. <i>Circulation</i> , 2001 , 104, 145-50	16.7	323
51	Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. <i>Journal of Molecular Biology</i> , 2001 , 311, 241-7	6.5	100
50	Effect of alcohol consumption on systemic markers of inflammation. <i>Lancet, The</i> , 2001 , 357, 763-7	40	425
49	Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. <i>Lancet, The</i> , 2001 , 358, 24-9	40	433
48	Immunoradiometric Assay of Circulating C-Reactive Protein: Age-related Values in the Adult General Population. <i>Clinical Chemistry</i> , 2000 , 46, 934-938	5.5	199
47	The protofilament substructure of amyloid fibrils. <i>Journal of Molecular Biology</i> , 2000 , 300, 1033-9	6.5	294
46	Molecular chaperone properties of serum amyloid P component. <i>FEBS Letters</i> , 2000 , 473, 199-202	3.8	41
45	Infection with <i>Helicobacter pylori</i> is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. <i>Circulation</i> , 1999 , 100, 2326-31	16.7	68

44	The physiological structure of human C-reactive protein and its complex with phosphocholine. <i>Structure</i> , 1999 , 7, 169-77	5.2	536
43	Acute phase response and evolution of familial Mediterranean fever. <i>Lancet, The</i> , 1999 , 353, 1415	4.0	133
42	C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. <i>Circulation</i> , 1999 , 99, 237-42	16.7	1410
41	Enhanced inflammatory response in patients with preinfarction unstable angina. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 1696-703	15.1	126
40	Hereditary renal amyloidosis associated with variant lysozyme in a large English family. <i>Nephrology Dialysis Transplantation</i> , 1999 , 14, 2639-44	4.3	66
39	Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998 , 25, 709-13	8.8	57
38	Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. <i>Kidney International</i> , 1998 , 53, 276-81	9.9	60
37	SAA1 alleles as risk factors in reactive systemic AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1998 , 5, 262-5	2.7	84
36	Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. <i>Circulation</i> , 1998 , 98, 2370-6	16.7	265
35	Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. <i>Journal of Experimental Medicine</i> , 1998 , 188, 1895-906	16.6	164
34	Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 1998 , 12, 208-10	2.5	18
33	Rapid Automated High Sensitivity Enzyme Immunoassay of C-Reactive Protein. <i>Clinical Chemistry</i> , 1998 , 44, 1358-1361	5.5	116
32	Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy. <i>Transplantation</i> , 1998 , 65, 1496-8	1.8	40
31	Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. <i>Age and Ageing</i> , 1997 , 26, 153-8	3	48
30	Amyloid and the gut. <i>Digestive Diseases</i> , 1997 , 15, 155-71	3.2	34
29	Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. <i>Journal of Molecular Biology</i> , 1997 , 269, 570-8	6.5	37
28	Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. <i>Journal of Molecular Biology</i> , 1997 , 272, 408-22	6.5	106
27	Common core structure of amyloid fibrils by synchrotron X-ray diffraction. <i>Journal of Molecular Biology</i> , 1997 , 273, 729-39	6.5	1402

26	The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: homology to self and the selection of T cell epitopes and T cell receptors. <i>Molecular Immunology</i> , 1997 , 34, 115-24	4.3	8
25	Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. <i>Nature Medicine</i> , 1997 , 3, 855-9	50.5	211
24	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. <i>Nature</i> , 1997 , 385, 787-93	50.4	980
23	Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. <i>American Journal of Cardiology</i> , 1997 , 80, 1104-8	3	8
22	Amyloidosis: a review of recent diagnostic and therapeutic developments. <i>British Journal of Haematology</i> , 1997 , 99, 245-56	4.5	143
21	Three dimensional structure of human C-reactive protein. <i>Nature Structural and Molecular Biology</i> , 1996 , 3, 346-54	17.6	263
20	Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. <i>Kidney International</i> , 1996 , 50, 282-9	9.9	51
19	Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. <i>Circulation</i> , 1996 , 94, 2373-80	16.7	101
18	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1995 , 2, 163-166	2.7	7
17	Tolerance and immunity to the inducible self antigen C-reactive protein in transgenic mice. <i>European Journal of Immunology</i> , 1995 , 25, 3489-95	6.1	16
16	The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. <i>New England Journal of Medicine</i> , 1994 , 331, 417-24	59.2	1895
15	Structure of pentameric human serum amyloid P component. <i>Nature</i> , 1994 , 367, 338-45	50.4	422
14	Comparative analyses of pentraxins: implications for protomer assembly and ligand binding. <i>Structure</i> , 1994 , 2, 1017-27	5.2	81
13	Molecular characterization of <i>Limulus polyphemus</i> C-reactive protein. I. Subunit composition. <i>FEBS Journal</i> , 1993 , 214, 91-7		37
12	Molecular characterization of <i>Limulus polyphemus</i> C-reactive protein. II. Asparagine-linked oligosaccharides. <i>FEBS Journal</i> , 1993 , 214, 99-110		9
11	Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). <i>Clinical Genetics</i> , 1991 , 40, 242-6	4	278
10	Tissue vitronectin in normal adult human dermis is non-covalently bound to elastic tissue. <i>Journal of Investigative Dermatology</i> , 1991 , 96, 747-53	4.3	19
9	Serum amyloid P component in chronic renal failure and dialysis. <i>Clinica Chimica Acta</i> , 1991 , 200, 191-9	6.2	70

8	Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. <i>New England Journal of Medicine</i> , 1990 , 323, 508-13	59.2	422
7	Tissue amyloid P component in normal human dermis is non-covalently associated with elastic fiber microfibrils. <i>Journal of Investigative Dermatology</i> , 1989 , 92, 53-8	4.3	16
6	Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro. <i>Journal of Investigative Dermatology</i> , 1988 , 91, 22-8	4.3	32
5	Imaging of experimental amyloidosis with 131I-labeled serum amyloid P component. <i>Arthritis and Rheumatism</i> , 1987 , 30, 1303-6		22
4	Murine type II collagen arthritis. Association of an acute-phase response with clinical course. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1131-8		11
3	Correlation of disease activity in systemic vasculitis with serum C-reactive protein measurement. A prospective study of thirty-eight patients. <i>European Journal of Clinical Investigation</i> , 1985 , 15, 89-94	4.6	12
2	Serum C-reactive protein levels in the management of infection in acute leukaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1984 , 20, 319-25		29
1	Immunohistochemical studies of amyloid P component distribution in normal human skin. <i>Journal of Investigative Dermatology</i> , 1983 , 80, 86-90	4.3	38